Farnesyl transferase inhibitor (Tipifarnib, zarnestra; z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabime (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

被引：4

作者：

Alvarez, Ricardo H.

Kantarijan, Hagop

Garcia-Manero, Guillermo

Estrov, Zeev

Ravandi-Kashani, Farhad

Verstovsek, Srdan

Giles, Francis

O'Brien, Susan

Koller, Charles Asa

Faderl, Stefan

Thomas, Deborah

Wright, John J.

Cortes, Jorge

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] NCI, CTEP, Bethesda, MD USA

来源：

关键词：

D O I：

10.1182/blood.V108.11.1999.1999

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1999

引用

页码：565A / 566A

页数：2